{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:24Z","timestamp":1793324784828,"version":"4.5.0"},"reference-count":123,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,21]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-year overall survival in the landmark ANDROMEDA trial. However, the current prognostic models were developed using patient populations treated with now-suboptimal therapies, creating a critical gap between risk stratification models and contemporary outcomes. This comprehensive review analyzes prognostic factors and progression biomarkers in AL, categorizing them into disease-specific (clone-related and organ-related) and patient-specific factors. Notably, traditional baseline biomarkers including difference between involved and uninvolved free light chains and bone marrow plasma cell burden are losing prognostic significance with effective clone-directed therapies. Emerging approaches show promise, including dynamic markers such as minimal residual disease by free light chain mass spectrometry, cardiac imaging parameters such as global longitudinal strain, and functional measures. There is an urgent need for validation studies and prognostic model refinement to identify patients at high risk who may benefit from interventions beyond anti\u2013plasma cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031651","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:29:54Z","timestamp":1772648994000},"page":"2448-2462","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[{"name":"1Department of Medicine, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-5267","authenticated-orcid":false,"given":"Yevgeniy","family":"Brailovsky","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[{"name":"2Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[{"name":"3Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joban","family":"Vaishnav","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Edward","family":"Hoffman","sequence":"additional","affiliation":[{"name":"5Department of Medicine, University of Miami Sylvester Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Griffin","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"7Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3140-2577","authenticated-orcid":false,"given":"David","family":"Wolinsky","sequence":"additional","affiliation":[{"name":"8Department of Nuclear Medicine, Cleveland Clinic, Weston, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-2994","authenticated-orcid":false,"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[{"name":"9Department of Neurology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-2498","authenticated-orcid":false,"given":"Helen","family":"Lachmann","sequence":"additional","affiliation":[{"name":"10National Amyloidosis Center, University College London, Royal Free Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Boursiquot","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Bampatsias","sequence":"additional","affiliation":[{"name":"12Department of Medicine, Icahn School of Medicine Mount Sinai, Elmhurst, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2106-3652","authenticated-orcid":false,"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[{"name":"13Amyloidosis Research Consortium, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4172-5612","authenticated-orcid":false,"given":"Phaedra","family":"Johnson","sequence":"additional","affiliation":[{"name":"13Amyloidosis Research Consortium, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-9757","authenticated-orcid":false,"given":"Jamie","family":"Zigterman","sequence":"additional","affiliation":[{"name":"13Amyloidosis Research Consortium, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Kazemzadeh","sequence":"additional","affiliation":[{"name":"13Amyloidosis Research Consortium, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Columbia University Irving Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"10National Amyloidosis Center, University College London, Royal Free Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 1","key":"2026052111214672700_bib1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2024-205077","article-title":"Subcutaneous daratumumab (DARA) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: overall survival and final major organ deterioration progression-free survival results from the phase 3 Andromeda Study","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2026052111214672700_bib2","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026052111214672700_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.27179","article-title":"Reduced early mortality with daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study","volume":"99","author":"Chakraborty","year":"2024","journal-title":"Am J Hematol"},{"issue":"4","key":"2026052111214672700_bib4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjh.20021","article-title":"Outcomes of daratumumab-bortezomib-thalidomide-dexamethasone in treatment-naive systemic AL amyloidosis","volume":"206","author":"Khwaja","year":"2025","journal-title":"Br J Haematol"},{"issue":"9","key":"2026052111214672700_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026052111214672700_bib6","first-page":"1598","article-title":"Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients","volume":"109","author":"Khwaja","year":"2024","journal-title":"Haematologica"},{"issue":"15","key":"2026052111214672700_bib7","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/bloodadvances.2024015528","article-title":"Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens","volume":"9","author":"Saunders","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026052111214672700_bib8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-019-0655-x","article-title":"Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"issue":"34","key":"2026052111214672700_bib9","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026052111214672700_bib10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2016.05.027","article-title":"The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation","volume":"22","author":"Dittus","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026052111214672700_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2018.1443439","article-title":"Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome","volume":"25","author":"Tovar","year":"2018","journal-title":"Amyloid"},{"issue":"3","key":"2026052111214672700_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/13506129.2022.2164488","article-title":"Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study","volume":"30","author":"Kumar","year":"2023","journal-title":"Amyloid"},{"issue":"11","key":"2026052111214672700_bib13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ajh.27450","article-title":"Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis","volume":"99","author":"Bazarbachi","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"2026052111214672700_bib14","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.bneo.2025.100092","article-title":"Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis","volume":"2","author":"Yohannan","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"24","key":"2026052111214672700_bib15","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2026052111214672700_bib16","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1182\/blood.2024025899","article-title":"Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy","volume":"144","author":"Chakraborty","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026052111214672700_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/13506129.2024.2406845","article-title":"Refining prognostication in systemic AL amyloidosis: limited value of dFLC","volume":"31","author":"Khwaja","year":"2024","journal-title":"Amyloid"},{"issue":"3","key":"2026052111214672700_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/s41375-018-0370-z","article-title":"Comparative analysis of staging systems in AL amyloidosis","volume":"33","author":"Muchtar","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2026052111214672700_bib19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026052111214672700_bib20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/13506129.2018.1490261","article-title":"Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis","volume":"25","author":"Nguyen","year":"2018","journal-title":"Amyloid"},{"issue":"3","key":"2026052111214672700_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/leu.2017.286","article-title":"Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains","volume":"32","author":"Sidana","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2026052111214672700_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026052111214672700_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"4","key":"2026052111214672700_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2017.1370421","article-title":"Attitudes about when and how to treat patients with AL amyloidosis: an international survey","volume":"24","author":"Milani","year":"2017","journal-title":"Amyloid"},{"issue":"5","key":"2026052111214672700_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"issue":"13","key":"2026052111214672700_bib26","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1182\/bloodadvances.2024012737","article-title":"The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review","volume":"8","author":"Ramachandran","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"2026052111214672700_bib27","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal - the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026052111214672700_bib28","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1373\/clinchem.2011.171314","article-title":"Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies","volume":"57","author":"Katzmann","year":"2011","journal-title":"Clin Chem"},{"issue":"3","key":"2026052111214672700_bib29","doi-asserted-by":"crossref","first-page":"030701","DOI":"10.11613\/BM.2021.030701","article-title":"Comparison of Freelite and N-Latex serum free light chain assays: a critical review","volume":"31","author":"Daves","year":"2021","journal-title":"Biochem Med"},{"issue":"7","key":"2026052111214672700_bib30","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2026052111214672700_bib31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026052111214672700_bib32","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate","year":"2021","journal-title":"Cancer Sci"},{"issue":"12","key":"2026052111214672700_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-022-00769-4","article-title":"Prognostic value of translocation 11;14 in patients with relapsed\/refractory myeloma receiving anti-CD38 therapy","volume":"12","author":"Mohyuddin","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026052111214672700_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026052111214672700_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2025-694","article-title":"An open-label multicenter phase 1\/2 trial of venetoclax-dexamethasone in Relapsed\/Refractory t(11;14)-positive systemic AL amyloidosis","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026052111214672700_bib36","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2026052111214672700_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ejh.13993","article-title":"Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies","volume":"111","author":"Fotiou","year":"2023","journal-title":"Eur J Haematol"},{"issue":"18","key":"2026052111214672700_bib38","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026052111214672700_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.26399","article-title":"Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab","volume":"97","author":"Szalat","year":"2022","journal-title":"Am J Hematol"},{"issue":"16","key":"2026052111214672700_bib40","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.22.01916","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies","volume":"41","author":"Burgos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026052111214672700_bib41","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052111214672700_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026052111214672700_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2016-06-721878","article-title":"The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026052111214672700_bib44","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/bloodadvances.2019001331","article-title":"Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis","volume":"4","author":"Staron","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2026052111214672700_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026052111214672700_bib46","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1002\/ajh.26562","article-title":"Impact of bone marrow minimal residual disease status on quality of organ response in systemic AL amyloidosis","volume":"97","author":"Chakraborty","year":"2022","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026052111214672700_bib47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood-2024-202995","article-title":"Clinical significance of measurable residual disease (MRD) in light-chain (AL) amyloidosis","volume":"144","author":"Lasa","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026052111214672700_bib48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026052111214672700_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-020-0291-8","article-title":"Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis","volume":"10","author":"Dispenzieri","year":"2020","journal-title":"Blood Cancer J"},{"issue":"25","key":"2026052111214672700_bib50","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026052111214672700_bib51","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2026052111214672700_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-020-00354-7","article-title":"Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis","volume":"10","author":"Sarosiek","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026052111214672700_bib53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-020-00355-6","article-title":"Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy","volume":"10","author":"Milani","year":"2020","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026052111214672700_bib54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137582","article-title":"Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from Andromeda","volume":"136","author":"Comenzo","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026052111214672700_bib55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/leu.2016.140","article-title":"Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2026052111214672700_bib56","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3324\/haematol.2016.147041","article-title":"Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type","volume":"101","author":"Muchtar","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2026052111214672700_bib57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.14908","article-title":"Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis","volume":"179","author":"Sachchithanantham","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2026052111214672700_bib58","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026052111214672700_bib59","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00277-021-04653-2","article-title":"Immunoparesis defined by heavy\/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease","volume":"100","author":"Isola","year":"2021","journal-title":"Ann Hematol"},{"issue":"12","key":"2026052111214672700_bib60","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1007\/s00277-024-06031-0","article-title":"Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease","volume":"103","author":"Lakhwani","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"2026052111214672700_bib61","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/bjh.16488","article-title":"Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma","volume":"189","author":"Chakraborty","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2026052111214672700_bib62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026052111214672700_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026052111214672700_bib64","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2023-175005","article-title":"Blood-based diagnostic assay for \u03bb light chain amyloidosis through quantification of an amyloidogenicity-indicating neo-epitope","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2026052111214672700_bib65","doi-asserted-by":"crossref","first-page":"e009038","DOI":"10.1161\/CIRCHEARTFAILURE.121.009038","article-title":"Proposed cardiac end points for clinical trials in immunoglobulin light chain amyloidosis: report from the Amyloidosis Forum Cardiac Working Group","volume":"15","author":"Maurer","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"3","key":"2026052111214672700_bib66","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026052111214672700_bib67","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15955","article-title":"Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers","volume":"186","author":"Rezk","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026052111214672700_bib68","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2024-202589","article-title":"Development of a risk prediction model for 6-month early mortality in patients with systemic light chain amyloidosis treated with daratumumab-based frontline therapy","volume":"144","author":"Mellgard","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026052111214672700_bib69","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3324\/haematol.2019.217695","article-title":"Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria","volume":"105","author":"Sharpley","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"2026052111214672700_bib70","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ajh.27545","article-title":"Feasibility of a biomarker-based screening for pre-symptomatic AL amyloidosis in patients with intermediate\/high-risk MGUS","volume":"100","author":"Mangiacavalli","year":"2025","journal-title":"Am J Hematol"},{"issue":"2","key":"2026052111214672700_bib71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13506129.2020.1713743","article-title":"The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis","volume":"27","author":"D'Souza","year":"2020","journal-title":"Amyloid"},{"issue":"3","key":"2026052111214672700_bib72","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/bjh.14889","article-title":"A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time","volume":"179","author":"Sanchorawala","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2026052111214672700_bib73","first-page":"1202","article-title":"Ethnicity in systemic AL amyloidosis may impact risk stratification","volume":"110","author":"Khwaja","year":"2025","journal-title":"Haematologica"},{"issue":"5","key":"2026052111214672700_bib74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/heartjnl-2013-304957","article-title":"High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis","volume":"100","author":"Dispenzieri","year":"2014","journal-title":"Heart"},{"issue":"18","key":"2026052111214672700_bib75","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","article-title":"The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"36","key":"2026052111214672700_bib76","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026052111214672700_bib77","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052111214672700_bib78","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2026052111214672700_bib79","first-page":"220","article-title":"Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival","volume":"109","author":"Oubari","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2026052111214672700_bib80","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","article-title":"Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial","volume":"4","author":"Minnema","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"7","key":"2026052111214672700_bib81","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026052111214672700_bib82","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.2024024623","article-title":"Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population","volume":"144","author":"Muchtar","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026052111214672700_bib83","first-page":"e53445","article-title":"Novel biomarkers in early detection of heart failure: a narrative review","volume":"16","author":"Kayani","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"2026052111214672700_bib84","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/eurheartj\/ehab507","article-title":"Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis","volume":"43","author":"Cohen","year":"2022","journal-title":"Eur Heart J"},{"issue":"25","key":"2026052111214672700_bib85","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026052111214672700_bib86","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/JCO-25-02558","article-title":"New validated staging system for light chain (AL) amyloidosis with stage IIIC defining ultra-poor risk: AL International Staging System","volume":"44","author":"Khwaja","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026052111214672700_bib87","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCIMAGING.112.978627","article-title":"Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study","volume":"6","author":"Banypersad","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"2026052111214672700_bib88","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"issue":"45","key":"2026052111214672700_bib89","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"issue":"15","key":"2026052111214672700_bib90","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2026052111214672700_bib91","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/ajh.27460","article-title":"Long-term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: validating the performance of the renal staging system","volume":"99","author":"Muchtar","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"2026052111214672700_bib92","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"2026052111214672700_bib93","first-page":"3032","article-title":"Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis","volume":"110","author":"Rauf","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"2026052111214672700_bib94","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1515\/cclm-2021-0912","article-title":"Prospective urinary albumin\/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients","volume":"60","author":"Basset","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"2026052111214672700_bib95","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/ajh.27716","article-title":"Cystatin C as biomarker for the evaluation of renal outcome in AL amyloidosis","volume":"100","author":"Theodorakakou","year":"2025","journal-title":"Am J Hematol"},{"issue":"10","key":"2026052111214672700_bib96","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","volume":"10","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"2026052111214672700_bib97","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2015060687","article-title":"Past decline versus current eGFR and subsequent ESRD risk","volume":"27","author":"Kovesdy","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2026052111214672700_bib98","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1093\/ndt\/gfs263","article-title":"Short-term change in kidney function and risk of end-stage renal disease","volume":"27","author":"Turin","year":"2012","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"2026052111214672700_bib99","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2026052111214672700_bib100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41591-025-04057-z","article-title":"A meta-analysis of albuminuria as a surrogate endpoint for kidney failure","volume":"32","author":"Heerspink","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"2026052111214672700_bib101","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2026052111214672700_bib102","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2006.06204.x","article-title":"Outcome of autologous stem cell transplantation for AL amyloidosis in the UK","volume":"134","author":"Goodman","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"2026052111214672700_bib103","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/07853890.2022.2069281","article-title":"The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement","volume":"54","author":"Zhao","year":"2022","journal-title":"Ann Med"},{"issue":"3","key":"2026052111214672700_bib104","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/ehf2.14671","article-title":"Prognostic mortality factors in advanced light chain cardiac amyloidosis: a prospective cohort study","volume":"11","author":"Zaroui","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"16","key":"2026052111214672700_bib105","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.21037\/atm-21-4033","article-title":"A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data from 1,064 Chinese patients","volume":"9","author":"Yan","year":"2021","journal-title":"Ann Transl Med"},{"issue":"5","key":"2026052111214672700_bib106","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","article-title":"Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients","volume":"82","author":"Park","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"2026052111214672700_bib107","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2026052111214672700_bib108","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.14586","article-title":"The six-minute walk test in patients with AL amyloidosis: a single centre case series","volume":"177","author":"Pulido","year":"2017","journal-title":"Br J Haematol"},{"issue":"20","key":"2026052111214672700_bib109","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/heartjnl-2021-320703","article-title":"Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis","volume":"108","author":"Cohen","year":"2022","journal-title":"Heart"},{"issue":"3","key":"2026052111214672700_bib110","doi-asserted-by":"crossref","first-page":"100833","DOI":"10.1016\/j.currproblcancer.2021.100833","article-title":"Focused review on nutritional status of patients with immunoglobulin light chain amyloidosis","volume":"46","author":"Grigoletti","year":"2022","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"2026052111214672700_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/cardiogenetics12020017","article-title":"Modified body mass index as a novel nutritional and prognostic marker in patients with cardiac amyloidosis","volume":"12","author":"Dongiglio","year":"2022","journal-title":"Cardiogenetics"},{"issue":"3","key":"2026052111214672700_bib112","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/13506129.2020.1737004","article-title":"Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis","volume":"27","author":"Caccialanza","year":"2020","journal-title":"Amyloid"},{"issue":"6","key":"2026052111214672700_bib113","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","article-title":"Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation","volume":"104","author":"Seldin","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2026052111214672700_bib114","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/ejh.14036","article-title":"Differences in patient-reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis","volume":"111","author":"D'Souza","year":"2023","journal-title":"Eur J Haematol"},{"issue":"5","key":"2026052111214672700_bib115","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.24676","article-title":"Hematology patient reported symptom screen to assess quality of life for AL amyloidosis","volume":"92","author":"Warsame","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2026052111214672700_bib116","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cardfail.2023.10.463","article-title":"Health-related quality of life as a predictor of heart failure admission and death in patients with amyloidosis","volume":"30","author":"Sideris","year":"2024","journal-title":"J Card Fail"},{"issue":"10","key":"2026052111214672700_bib117","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.cardfail.2020.09.337","article-title":"Patient reported outcomes in amyloidosis cardiomyopathy","volume":"26","author":"Siu","year":"2020","journal-title":"J Card Fail"},{"issue":"2","key":"2026052111214672700_bib118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-021-00412-8","article-title":"Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change","volume":"11","author":"D'Souza","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026052111214672700_bib119","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s41669-019-0122-7","article-title":"Associations between health-related quality of life and self-reported emergency room department visits and inpatient hospitalizations: insights from a secondary data analysis of patients with light-chain (AL) amyloidosis","volume":"3","author":"McCausland","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"2026052111214672700_bib120","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/bjh.18645","article-title":"Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light-chain amyloidosis","volume":"201","author":"Cohen","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2026052111214672700_bib121","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2025-692","article-title":"Phase 1\/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis","volume":"146","author":"Chakraborty","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052111214672700_bib122","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1182\/blood-2025-5808","article-title":"A phase I\/II, open label, study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: interim report of phase I results","volume":"146","author":"Hossain","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052111214672700_bib123","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2025-696","article-title":"First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R\/R light chain (AL) amyloidosis, nxc-201","volume":"146","author":"Landau","year":"2025","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1182\/blood.2026035071","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/21\/2448\/2521256\/blood_bld-2025-031651-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/21\/2448\/2521256\/blood_bld-2025-031651-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:22:05Z","timestamp":1779376925000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/21\/2448\/566919\/Prognostic-factors-and-progression-biomarkers-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":123,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,5,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031651","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,21]]},"published":{"date-parts":[[2026,5,21]]}}}